For the Inventor, By the Inventor

Enter assignee name

Banvaktsvagen, Sweden

Kancera Ab

USPTO Granted Patents = 15

% Expired Patents = 46.7

EPO Patents = 9

Forward Citations = 57

Loading Chart...

Loading Chart...

22 inventors (with patents filed for the assignee):

Jan Vågberg (9 out of 13 patents)

Styrbjörn Byström (9 out of 12 patents)

Elisabeth Olsson (6 out of 6 patents)

4. Mattias Jönsson (5 out of 5 patents)

5. Håkan Mellstedt (4 out of 4 patents)

6. Jessica Martinsson (3 out of 3 patents)

7. Rune Ringom (2 out of 9 patents)

8. Kristin Hammer (2 out of 5 patents)

9. Lars Krüger (2 out of 5 patents)

10. Ingrid Teige (2 out of 12 patents)

11. Katarina Färnegårdh (2 out of 2 patents)

12. Katarina Faernegardh (2 out of 2 patents)

13. Mattias Joensson (2 out of 2 patents)

14. Evert Homan (1 out of 10 patents)

15. Thomas Helleday (1 out of 11 patents)

15 patents: Sort by Forward Citations

1. 12264165 - Process for the stereoselective preparation of chiral 2-[(hetero) arylalkylsulfanyl]pyrimidines and products obtainable therefrom (2025-04-01),

2. 12060380 - Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 (2024-08-13),

3. 11691988 - Process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom (2023-07-04),

4. 11660303 - 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity (2023-05-30),

5. 11542281 - Process for the steroselective preparation of chiral 2- [(hetero)arylalkylsulfanyl] pyrimidines and products obtainable therefrom (2023-01-03),

6. 11339183 - Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 (2022-05-24),

7. 11008318 - 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity (2021-05-18),

8. 10654814 - Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity (2020-05-19),

9. 10550113 - 2-phenyl-3H-imidazo[4,5-B]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity (2020-02-04),

10. 10512634 - Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity (2019-12-24),

11. 10000449 - Bisarylsulfonamides useful in the treatment of inflammation and cancer (2018-06-19),

12. 9718809 - Bisarylsulfonamides useful in the treatment of inflammation and cancer (2017-08-01),

13. 9266952 - Antibodies against ROR1 and uses thereof (2016-02-23),

14. 9233946 - Sulfonamide compounds (2016-01-12),

15. 9150647 - Biological inhibitors of ROR1 capable of inducing cell death (2015-10-06),

Company Overview

Kancera AB is a biotechnology company based in Sweden, focusing on the development of innovative therapies for cancer and inflammatory diseases. The company specializes in small molecule drug candidates that target specific biological pathways, aiming to improve treatment outcomes and patient quality of life. Kancera's research efforts are centered on precision medicine, leveraging advanced scientific methodologies to address unmet medical needs in oncology and related fields.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

15 Patents

#1 in Banvaktsvagen

#432 in Sweden

#39,921 in the World

Banvaktsvagen, Sweden

Kancera Ab

Forward Citations = 57

22 inventors:

Jan Vågberg (9 out of 13 patents)

Styrbjörn Byström (9 out of 12 patents)

Elisabeth Olsson (6 out of 6 patents)

4. Mattias Jönsson (5 out of 5 patents)

5. Håkan Mellstedt (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Kancera Ab. Retrieved from https://idiyas.com/company/kancera-ab

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…